HYRIMOZ is a prescription medication that belongs to a class of drugs known as biologic therapies, specifically a biosimilar to the original biologic drug adalimumab. It is designed to mimic the effects of naturally occurring substances in the body and works by targeting and blocking a protein called tumor necrosis factor (TNF), which plays a key role in inflammation and immune system responses. By inhibiting TNF, HYRIMOZ helps reduce inflammation and can be used to treat a variety of autoimmune conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Its administration is typically through subcutaneous injection and it is intended for use under the guidance of healthcare professionals to ensure safety and efficacy for individuals with these conditions.